Study DMX-IB 201 is a Phase 1/2a study of ibogaine consisting of an initial single ascending
dose escalation stage to determine the maximum tolerated dose (MTD) or treat-to-target dose
(TTD) in healthy volunteers, followed by a randomized, double-blind, placebo-controlled proof
of concept stage to demonstrate the efficacy, safety and tolerability of the selected dose in
opioid-dependent patients who seek medically supervised opioid withdrawal
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
DemeRx IB, Inc.
Collaborators:
ERT: Clinical Trial Technology Solutions MAC Clinical Research